Chemo Fog

Short Introduction and History.- Patient's Perspective.- Oncology Nurse's Perspective.- Oncology Pharmacist's Perspective.- The Impact of Chemo Brain on the Patient with a High-Grade Glioma.- Neurocognitive Effects of Childhood Cancer Treatment.- The Economic Burden.- Designing Conceptual Model-Based Research in Chemotherapy-Related Changes in Cognitive Function.- Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment.- Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment.- Chemotherapy Associated Central Nervous System Damage.- Is Systemic Anti-Cancer Therapy Neurotoxic? Does Chemo Brain Exist? And Should We Rename It?.- Evaluation of Multiple Neurotoxic Outcomes in Cancer Chemotherapy.- Chemotherapy-Related Visual System Toxicity.- The Possible Role of Cytokines in Chemotherapy-Induced Cognitive Deficits.- Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy.- Combination Analysis.- Animal Models.- Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction.- Effects of 5-FU.- Future Directions.

ROBERT B. RAFFA, PhD, is Professor of Pharmacology and Chair of theDepartment of Pharmaceutical Sciences at Temple University School of Pharmacy in Philadelphia, Pennslyvania. He holds B Chem E and BS degrees in Chemical Engineering and Physiological Psychology, MS degrees in Biomedical Engineering and Toxicology, and a PhD in Pharmacology. He is the co-author or editor of several books on pharmacology and thermodynamics and over 200 articles in refereed journals, and is active in NIH-funded research, editorial, and professional society activities. Dr. Raffa became co-founder and president of the Forget-Me-Not Foundation in 2009.RONALD J. TALLAR IDA, PhD, is a Professor of Pharmacology at TempleUniversity School of Medicine. He has BS and MS degrees in physics/mathematics from Drexel University and a PhD in pharmacology. His work, primarily concerned with quantitative aspects of pharmacology, is represented in more than 250 published works that include eight books he has authored or co-authored. Dr. Tallarida currentlyteaches, serves on editorial advisory boards, conducts NIH-funded research, and is active in professional societies. Dr. Tallarida became co-founder and Vice-president of the Forget-Me-Not Foundation in 2009.